<DOC>
	<DOCNO>NCT02496897</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity FP-02.2 , new therapeutic Hepatitis B vaccine , administer add-on therapy entecavir tenofovir . Seventy-two HBeAg-negative subject randomize receive low high dose vaccine , presence absence IC31® adjuvant , receive placebo IC31® adjuvant alone .</brief_summary>
	<brief_title>Phase I Safety Immunogenicity FP-02.2 Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Male female subject age 1865 year . 2 . Diagnosed chronic hepatitis B define HBsAg positive least 24 month . 3 . Subject receive entecavir tenofovir least 2 year stable dose least 6 month prior screen . 4 . HBeAg negative least 2 year prior inclusion study . 5 . HBV DNA &lt; 50 IU/mL ≥ 12 month 6 . ALT/AST ≤ 1.5 x ULN via local laboratory Screening Visit 7 . Able give write informed consent participate 8 . Females fulfil one follow criterion : 1 . At least one year menopausal 2 . Surgically sterile 3 . Samesex relationship 4 . WOCBP surgically sterilize laboratory confirm menopausal status require use highly effective contraceptive measure low use dependency screen one menstrual cycle last dose IMP ( Day 58 ) : Combined ( oestrogen progestogencontaining ) hormonal contraception associate inhibition ovulation Progestogenonly hormonal contraception implant associate inhibition ovulation Intrauterine device ( IUD ) Intrauterine hormonereleasing system ( IUS ) Bilateral tubal occlusion Vasectomised partner must medical assessment successful surgery . From screen one menstral cycle last dose IMP ( day 57 ) . Subjects practice true abstinence exclusively sex partner need use contraception , provide line prefer usual lifestyle . Periodic abstinence ( eg calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Should subject stop practice true abstinence , must use contraception described . Males fulfil one follow criterion : Surgically sterile Willing abstain sexual intercourse use reliable form contraception ( e.g . condom ) , sex pregnant nonpregnant woman childbearing potential , screen 3 month final dose IMP . Surgically sterilise postmenopausal female partner samesex relationship . 1 . Liver disease chronic hepatitis B ( diagnosis steatosis permit provide inclusion criterion 6 met ) . 2 . Evidence Liver cirrhosis Fibroscan screening ( Liver cirrhosis define Fibroscan measurement &gt; 11.5 KPa ) , previous history evidence cirrhosis radiological imaging , Fibroscan liver biopsy . 3 . Positive serology HIV1 HIV2 HCV HDV antibody . 4 . Immunodeficient autoimmune condition due disease medication e.g . systemic steroid within previous 12 week . ( Topical inhale steroid permissible ) . 5 . Clinically relevant comorbidity , e.g . autoimmune disease . 6 . Clinically relevant anaemia leukopenia opinion investigator . 7 . Cancer treatment cancer within 3 year prior screen exclude basal cell carcinoma skin , allow . 8 . Known suspected intolerance hypersensitivity IMP closely related compound state ingredient . 9 . Receipt IMP within 90 day prior screen currently receive IMP intent receive IMP . 10 . Current substance alcohol abuse opinion Investigator would interfere compliance interpretation study result . 11 . Any condition opinion Investigator might interfere study objective . 12 . Pregnant breastfeeding . 13 . Subjects receive , 6 month period prior screening , medication treatment may adversely affect immune system allergy injection , immunoglobulin , interferon , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) . Immunosuppressive treatment azathioprine mercaptopurine permit 6 month prior screen . 14 . Administration live vaccine ( live influenza vaccination live travel vaccination ) 10 day prior screen visit Day 85 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>